Cover Image
市場調查報告書

MediPoint:神經血管介入 - 亞太地區市場分析與預測

MediPoint: Neurovascular Interventions - APAC Analysis and Market Forecasts

出版商 GlobalData 商品編碼 301169
出版日期 內容資訊 英文 342 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:神經血管介入 - 亞太地區市場分析與預測 MediPoint: Neurovascular Interventions - APAC Analysis and Market Forecasts
出版日期: 2014年04月30日 內容資訊: 英文 342 Pages
簡介

全球神經血管介入正以2位數的大幅速度在急速成長。由於神經介入技術與低侵入性治療技術急速進步,未來可治療的疾病也在日益增加。神經血管介入市場分為血管堵塞、血管再生、機械除去血栓、進入/支援等四個領域。

本報告提供亞太地區的腦血管疾病(顱內動脈瘤/動靜脈畸形,動脈粥狀硬化等)治療用的神經血管介入市場相關分析,疾病概要和市場結構,目前未滿足需求,主要的推動及阻礙市場要素,今後的市場機會,現在臨床實驗中的主要產品,全球整體及主要10個國家的市場趨勢(過去3年的實際成果值和今後7年的預測值),各類型產品的詳細趨勢,再加上主要企業簡介等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

第3章 臨床結果

  • 疾病的管理
    • 顱內動脈瘤
    • 顱內動靜脈畸形
    • 硬薄膜動靜脈瘺
    • 顱內/顱外動脈粥狀硬化
    • 中風
  • 治療方式
    • 概要
    • 醫藥/化療
    • 外科療法
    • 血管內療法

第4章 產業概要

  • 概況
  • 治療的趨勢
    • 顱內動脈瘤
    • 顱內動靜脈畸形
    • 動脈粥狀硬化
    • 急性缺血性中風
  • 市場進入
    • 法規的流程
    • 醫生的認識·決策流程
    • 臨床診療的變化
    • 臨床資料的不足
    • 地區水準的管理
    • 成本的考慮
    • 醫療費給付的趨勢
  • 企業合併·收購(M&A)/主要的夥伴關係
  • 經濟上的影響
    • 顱內動脈瘤/動靜脈畸形的情況
    • 中風的情況
  • 第5章 未滿足需求
  • 概要
  • 訓練、實績、醫師訓練指南的需求
  • 臨床資料的不足
  • 改善急性缺血性中風的管理
  • 處理複雜化外科療法
  • 手術夾的問題
  • 欠缺處理未破裂顱內動脈瘤治療策略
  • 複雜形態、規模的動脈瘤有效治療法
  • 顱內動靜脈畸形的治療困難
  • 處理球囊血管新生法相關課題
  • 處理神經血管用支撐術相關課題
  • 雙重抗血小板療法(DAPT)的複雜化
  • 改善醫藥療法的需求
  • 緩和就醫需求

第6章 市場機會分析

  • 神經血管介入市場
  • 改善介入神經放射學設備的設計
  • 複雜的顱內動脈瘤/動靜脈畸形的治療相關課題
  • 以多數患者為對象的治療方法
  • 急性缺血性中風患者治療方法的最佳化
  • 開發藥物釋放型設備
  • 新興市場

第7章 推動市場要素與課題

  • 推動市場要素
    • 疾病得病率的上升
    • 改善血管內栓塞臨床結果
    • 改變血管支架/球囊輔助栓塞的治療法
    • 可行的複雜顱內動脈瘤治療選擇
    • 治療動脈瘤用線圈以外的替代性的閉塞形成設備
    • 顱內動靜脈畸形的血管內閉塞
    • 治療顱內動靜脈畸形的影像診斷
    • 頸動脈硬化性疾病的支架
    • 小型支架設備
    • 改善機械除血栓設備的最大通率
    • 成本控制
    • 得到長期性、具成本效率資料的可能性
  • 市場課題
    • 介入神經放射學治療·設備的複雜性
    • 臨床資料的不足
    • 高治療費
    • 醫療費給付額的不足
    • 缺乏生物活性/塗層線圈的優勢
    • 中風治療的替代性方法
    • 法規上的問題:美國FDA和EC標示
    • 降低醫療費的動向與醫療費給付
    • 可用的風險投資
    • 醫療設備的貨品稅

第8章 競爭力的評估

  • 概要
  • 亞太地區市場佔有率
  • 已上市產品(計29產品)

第9章 開發中產品的評估

  • 概要
  • 各開發階段的開發中產品
  • 產品簡介(計12產品)

第10章 臨床實驗分析

  • 概要
  • 值得注意的臨床實驗
    • 血管堵塞
    • 血流重建
    • 血管再生
    • 機械除去血栓

第11章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介(計30公司份)

第12章 市場未來展望

  • 概要
  • 各國市場預測
    • 日本
    • 中國
    • 印度

第13章 附錄

圖表一覽

目錄
Product Code: GDME1099CFR

The global neurovascular interventions market is a vast, double-digit market that consists of innovative and emerging technologies. Rapid advances in the field of neurovascular interventions and development of minimally invasive techniques have greatly expanded the potential of therapeutic applications. The neurovascular interventions market consists of four device segments including embolization, revascularization, mechanicalthrombectomy and access/support devices.

The APAC neurovascular interventions market is a vast and dynamic market that consists of innovative and emerging technologies. Neurointerventional devices can be used to treat a variety of cerebrovascular indications such as intracranial aneurysms, AVMs, and dural AVFs, atherosclerotic disease, and stroke. In this report, the neurointerventional market encompasses embolization, revascularization, mechanical thrombectomy, and access/support devices.

Scope

  • An overview of Neurovascular Interventions, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized APAC Neurovascular Interventions market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Neurovascular Interventions.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Neurovascular Interventions sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving the APAC Neurovascular Interventions market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in APAC Neurovascular Interventions market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in APAC Neurovascular Interventions market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst

3. Clinical Outcomes

  • 3.1. Disease Management
    • 3.1.1. Intracranial Aneurysms
    • 3.1.2. Intracranial Arteriovenous Malformations
    • 3.1.3. Dural Arteriovenous Fistulas
    • 3.1.4. Intracranial and Extracranial Atherosclerotic Disease
    • 3.1.5. Stroke
  • 3.2. Treatment Modalities
    • 3.2.1. Overview
    • 3.2.2. Medical/Chemical Therapy
    • 3.2.3. Surgical Therapy
    • 3.2.4. Endovascular Therapy

4. Industry Overview

  • 4.1. Overview
  • 4.2. Procedure Trends
    • 4.2.1. Intracranial Aneurysms
    • 4.2.2. Intracranial Arteriovenous Malformations
    • 4.2.3. Atherosclerotic Disease
    • 4.2.4. Acute Ischemic Stroke
  • 4.3. Market Access
    • 4.3.1. Regulatory Process
    • 4.3.2. Physician Perception and Decision Making Process
    • 4.3.3. Variations in Clinical Practice
    • 4.3.4. Lack of Clinical Data
    • 4.3.5. Regional-Level Control
    • 4.3.6. Cost-Considerations
    • 4.3.7. Reimbursement Trends
  • 4.4. Mergers and Acquisitions/Key Partnerships
    • 4.4.1. Covidien and Nfocus Neuromedical
    • 4.4.2. Stryker Corporation and Surpass Medical
    • 4.4.3. Covidien and MindFrame
    • 4.4.4. Covidien and Reverse Medical Corporation
    • 4.4.5. Stryker Corporation and Boston Scientific Neurovascular
    • 4.4.6. Stryker Corporation and Concentric Medical
    • 4.4.7. Covidien and ev3
    • 4.4.8. Medtronic and Invatec
    • 4.4.9. Johnson & Johnson and Micrus Endovascular
    • 4.4.10. ev3 and Chestnut Medical Technologies
    • 4.4.11. Boston Scientific Corporation and Guidant Corporation
  • 4.5. Economic Impact
    • 4.5.1. Economic Impact of Intracranial Aneurysms and Arteriovenous Malformations
    • 4.5.2. Economic Impact of Stroke

5. Unmet Needs

  • 5.1. Overview
  • 5.2. Need for Practice, Performance, and Physician Training Guidelines
  • 5.3. Lack of Clinical Data
  • 5.4. Improve Management of Acute Ischemic Stroke
  • 5.5. Address Complications of Surgical Therapy
  • 5.6. Addressing the Challenges of Surgical Clipping
  • 5.7. Lack of Optimal Treatment Strategy for Unruptured Intracranial Aneurysms
  • 5.8. Need for Effective Therapies for Complex Aneurysm Morphologies and Sizes
  • 5.9. Difficulty in Treating Intracranial Arteriovenous Malformations
  • 5.10. Eliminating Mechanisms of Failure with Balloon Angioplasty
  • 5.11. Addressing Challenges of Neurovascular Stenting
    • 5.11.1. Risk of Post-Procedural Complications
    • 5.11.2. In-Stent Restenosis
    • 5.11.3. Stent Navigation
  • 5.12. Complications of Dual Antiplatelet Therapy
  • 5.13. Need to Improve Medical Therapy
  • 5.14. Improve Ease of Access

6. Market Opportunity Analysis

  • 6.1. Neurovascular Interventions Market
  • 6.2. Improve Neurointerventional Device Design
  • 6.3. Challenges in Treating Complex Intracranial Aneurysms and Arteriovenous Malformations
    • 6.3.1. Intracranial Aneurysms
    • 6.3.2. Intracranial Arteriovenous Malformations
  • 6.4. Target Challenging Patient Populations
  • 6.5. Optimize Care for Acute Ischemic Stroke Patients
  • 6.6. Development of Drug-Eluting Devices
  • 6.7. Emerging Markets

7. Market Drivers and Barriers

  • 7.1. Market Drivers
    • 7.1.1. Rising Prevalence of Disease
    • 7.1.2. Improved Clinical Outcomes with Endovascular Coiling
    • 7.1.3. Remodeling Techniques with Stent and Balloon-Assisted Coiling
    • 7.1.4. Viable Therapeutic Option for Challenging/Complex Intracranial Aneurysms
    • 7.1.5. Alternative Non-Coiling Embolization Devices for Aneurysm Treatment
    • 7.1.6. Endovascular Embolization of Intracranial Arteriovenous Malformations
    • 7.1.7. Imaging Assessment for Intracranial Arteriovenous Malformation Treatment
    • 7.1.8. Stenting for Carotid Atherosclerotic Disease
    • 7.1.9. Low-Profile Stent Systems
    • 7.1.10. Improved Recanalization Rates with Mechanical Thrombectomy Devices
    • 7.1.11. Cost Savings
    • 7.1.12. Availability of Long-Term and Cost-Effective Data
  • 7.2. Market Barriers
    • 7.2.1. Complications of Neurointerventional Procedures and Devices
    • 7.2.2. Lack of Clinical Data
    • 7.2.3. High Cost of Treatment
    • 7.2.4. Lack of Reimbursement
    • 7.2.5. Lack of Superiority of Bioactive/Coated Coils
    • 7.2.6. Alternative Technologies for Stroke Therapy
    • 7.2.7. Regulatory Challenges: US Food and Drug Administration and European Conformity Mark
    • 7.2.8. Healthcare Cost-Cutting and Reimbursement
    • 7.2.9. Availability of Venture Capital
    • 7.2.10. Medical Device Excise Tax

8. Competitive Assessment

  • 8.1. Overview
  • 8.2. APAC Market Share
  • 8.3. Marketed Products
    • 8.3.1. Aachen Resonance
    • 8.3.2. Abbott Vascular
    • 8.3.3. Acandis
    • 8.3.4. B. Braun
    • 8.3.5. BALT Extrusion
    • 8.3.6. Blockade Medical
    • 8.3.7. Boston Scientific Corporation
    • 8.3.8. Contego Medical
    • 8.3.9. Cook Medical
    • 8.3.10. Covidien
    • 8.3.11. Gardia Medical
    • 8.3.12. Gore Medical
    • 8.3.13. InspireMD
    • 8.3.14. ITGI Medical
    • 8.3.15. Johnson & Johnson
    • 8.3.16. Medikit
    • 8.3.17. Medtronic
    • 8.3.18. Merlin MD
    • 8.3.19. MicroPort Scientific Corporation
    • 8.3.20. Minvasys
    • 8.3.21. Neuravi
    • 8.3.22. Optimed
    • 8.3.23. Penumbra
    • 8.3.24. Phenox GmbH
    • 8.3.25. Reverse Medical
    • 8.3.26. Sequent Medical
    • 8.3.27. Stryker Neurovascular Intervention
    • 8.3.28. Terumo Corporation
    • 8.3.29. Valor Medical

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Pipeline by Stage of Development
  • 9.3. Product Profiles
    • 9.3.1. Aneurysm Occlusion Saddle
    • 9.3.2. Ballstent Microcatheter
    • 9.3.3. Blood Clot Removing Device
    • 9.3.4. EKOS' EkoSonic Small Vessel Endovascular System
    • 9.3.5. Flow-Diverting Thin-Film Nitinol Covered Stent
    • 9.3.6. Ischemic Stroke System
    • 9.3.7. Janjua Aneurysm Net
    • 9.3.8. Multilayer Aneurysm Repair System
    • 9.3.9. NAVIMAX
    • 9.3.10. Palmaz Scientific Stents
    • 9.3.11. Silk Road System
    • 9.3.12. Transcranial Thrombectomy Catheter

10. Clinical Trial Analysis

  • 10.1. Overview
  • 10.2. Clinical Trials to Watch
    • 10.2.1. Embolization
    • 10.2.2. Flow Diversion
    • 10.2.3. Revascularization
    • 10.2.4. Mechanical Thrombectomy

11. Current and Future Players

  • 11.1. Overview
  • 11.2. Trends in Corporate Strategy
  • 11.3. Company Profiles
    • 11.3.1. BALT Extrusion
    • 11.3.2. Covidien
    • 11.3.3. Johnson & Johnson
    • 11.3.4. Penumbra
    • 11.3.5. Stryker Corporation
    • 11.3.6. Terumo Corporation
    • 11.3.7. Abbott Vascular
    • 11.3.8. Boston Scientific Corporation
    • 11.3.9. Cook Medical
    • 11.3.10. Gore Medical
    • 11.3.11. Medtronic
    • 11.3.12. Aachen Resonance
    • 11.3.13. Acandis
    • 11.3.14. B. Braun
    • 11.3.15. Blockade Medical
    • 11.3.16. Contego Medical
    • 11.3.17. Gardia Medical
    • 11.3.18. InspireMD
    • 11.3.19. ITGI Medical
    • 11.3.20. Medikit
    • 11.3.21. Merlin MD
    • 11.3.22. MicroPort Scientific Corporation
    • 11.3.23. Minvasys
    • 11.3.24. Neuravi
    • 11.3.25. Optimed
    • 11.3.26. Phenox GmBH
    • 11.3.27. Reverse Medical
    • 11.3.28. Sequent Medical
    • 11.3.29. Valor Medical
    • 11.3.30. Other Companies

12. Market Outlooks

  • 12.1. Overview
  • 12.2. Country-Specific Market Outlook
    • 12.2.1. Japan
    • 12.2.2. China
    • 12.2.3. India

13. Appendix

  • 13.1. Bibliography
  • 13.2. Abbreviations
  • 13.3. Report Methodology
    • 13.3.1. Overview
    • 13.3.2. Coverage
    • 13.3.3. Secondary Research
  • 13.4. Physicians and Specialists Included in this Study
    • 13.4.1. Vivek Gupta, MD
    • 13.4.2. Zsolt Kulscar, MD, PhD
    • 13.4.3. Salvatore Mangiafico, MD
    • 13.4.4. Thanh Nguyen, MD, FRCPc
    • 13.4.5. Eduardo Wajnberg, MD
    • 13.4.6. Phil White, MD
    • 13.4.7. Osama O Zaidat, MD, MS, FAAN, FAHA
  • 13.5. Primary Research
    • 13.5.1. Primary Research - Key Opinion Leader Interviews
    • 13.5.2. Expert Panel Validation
  • 13.6. Forecasting Methodology
  • 13.7. About the Authors
    • 13.7.1. Analysts
    • 13.7.2. Global Head of Healthcare
  • 13.8. About MediPoint
  • 13.9. About GlobalData
  • 13.10. Disclaimer

List of Tables

  • Table 1: Complications of Cerebral Artery Bypass Surgery
  • Table 2: Types of Cerebral Embolic Protection Devices
  • Table 3: Reimbursement Classification of Medical Devices in Japan
  • Table 4: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 5: Aachen Resonance Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 6: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 7: Abbott Vascular Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 8: Acandis Neurovascular Intervention Marketed Products
  • Table 9: Acandis Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 10: B. Braun Neurovascular Intervention Marketed Product
  • Table 11: B. Braun Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 12: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 13: BALT Extrusion Neurovascular Intervention Marketed Access Products
  • Table 14: BALT Extrusion Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 15: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 16: Blockade Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 17: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 18: Boston Scientific Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 19: Contego Medical Neurovascular Intervention Marketed Product
  • Table 20: Contego Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 21: Cook Medical Neurovascular Intervention Marketed Products
  • Table 22: Cook Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 23: Covidien Neurovascular Interventional Marketed Products
  • Table 24: Covidien Neurovascular Intervention Marketed Access Products
  • Table 25: Covidien Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 26: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 27: Gardia Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 28: Gore Medical Neurovascular Intervention Marketed Products
  • Table 29: Gore Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 30: InspireMD Neurovascular Intervention Marketed Product
  • Table 31: InspireMD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 32: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 33: ITGI Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 34: Codman Neurovascular Marketed Embolization Products
  • Table 35: Codman Neurovascular Marketed Mechanical Thrombectomy and Access Products
  • Table 36: Codman Neurovascular's (Codman & Shurtleff) Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 37: Cordis Corporation Marketed Neurointerventional Products
  • Table 38: Cordis Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 39: Medikit Neurovascular Intervention Marketed Products
  • Table 40: Medikit Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 41: Medtronic Neurovascular Intervention Marketed Products
  • Table 42: Medtronic Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 43: Merlin MD Neurovascular Intervention Marketed Product
  • Table 44: Merlin MD Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 45: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 46: MicroPort Scientific Corporation Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 47: Minvasys Neurovascular Intervention Marketed Product
  • Table 48: Minvasys Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 49: Neuravi Neurovascular Intervention Marketed Product
  • Table 50: Neuravi Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 51: Optimed Neurovascular Intervention Marketed Products
  • Table 52: Optimed Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 53: Penumbra Neurovascular Intervention Marketed Products
  • Table 54: Penumbra Marketed Neurovascular Access Products
  • Table 55: Penumbra Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 56: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 57: Phenox GmbH Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 58: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 59: Reverse Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 60: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 61: Sequent Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 62: Stryker Neurovascular Intervention Marketed Products
  • Table 63: Stryker Neurovascular Intervention Marketed Mechanical Thrombectomy and Access Products
  • Table 64: Stryker Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 65: Terumo Europe N.V. and Terumo Interventional Systems Marketed Neurointerventional Products
  • Table 66: Terumo Corporation Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 67: MicroVention Neurovascular Intervention Marketed Products
  • Table 68: MicroVention Marketed Neurovascular Access Products
  • Table 69: MicroVention Neurovascular Product Portfolio SWOT Analysis, 2014
  • Table 70: Valor Medical Neurovascular Intervention Marketed Products
  • Table 71: Valor Medical Neurovascular Intervention Product Portfolio SWOT Analysis, 2014
  • Table 72: Global Neurovascular Interventions Pipeline Products
  • Table 73: Aneurysm Occlusion Saddle SWOT Analysis, 2014
  • Table 74: EKOS EkoSonic SV System SWOT Analysis, 2014
  • Table 75: Flow-Diverting Thin-Film Nitinol Covered Stent SWOT Analysis, 2014
  • Table 76: Janjua Aneurysm Net SWOT Analysis, 2014
  • Table 77: Multilayer Aneurysm Repair System SWOT Analysis, 2014
  • Table 78: NAVIMAX SWOT Analysis, 2014
  • Table 79: Palmaz Scientific Stents SWOT Analysis, 2014
  • Table 80: Silk Road System SWOT Analysis, 2014
  • Table 81: BALT Extrusion Company Profile
  • Table 82: BALT Extrusion Neurovascular Intervention Marketed Products
  • Table 83: BALT Extrusion SWOT Analysis, 2014
  • Table 84: Covidien Company Profile
  • Table 85: Covidien Neurovascular Intervention Marketed Products
  • Table 86: Covidien SWOT Analysis, 2014
  • Table 87: Codman & Shurtleff Company Profile
  • Table 88: Codman & Shurtleff Neurovascular Intervention Marketed Products
  • Table 89: Codman & Shurtleff SWOT Analysis, 2014
  • Table 90: Cordis Corporation Company Profile
  • Table 91: Cordis Corporation Neurovascular Intervention Marketed Products
  • Table 92: Cordis Corporation SWOT Analysis, 2014
  • Table 93: Penumbra Company Profile
  • Table 94: Penumbra Neurovascular Intervention Marketed Products
  • Table 95: Penumbra SWOT Analysis, 2014
  • Table 96: Stryker Corporation Company Profile
  • Table 97: Stryker Corporation Neurovascular Intervention Marketed Products
  • Table 98: Stryker Corporation SWOT Analysis, 2014
  • Table 99: Terumo Corporation Company Profile
  • Table 100: Terumo Europe N.V. and Terumo Interventional Systems Neurovascular Intervention Marketed Products
  • Table 101: MicroVention Neurovascular Intervention Marketed Products
  • Table 102: Terumo Corporation SWOT Analysis, 2014
  • Table 103: Abbott Vascular Company Profile
  • Table 104: Abbott Vascular Neurovascular Intervention Marketed Products
  • Table 105: Abbott Vascular SWOT Analysis, 2014
  • Table 106: Boston Scientific Corporation Company Profile
  • Table 107: Boston Scientific Neurovascular Intervention Marketed Products
  • Table 108: Boston Scientific Corporation SWOT Analysis, 2014
  • Table 109: Cook Medical Company Profile
  • Table 110: Cook Medical Neurovascular Intervention Marketed Products
  • Table 111: Cook Medical SWOT Analysis, 2014
  • Table 112: Gore Medical Company Profile
  • Table 113: Gore Medical Neurovascular Intervention Marketed Products
  • Table 114: Gore Medical SWOT Analysis, 2014
  • Table 115: Medtronic Company Profile
  • Table 116: Medtronic Neurovascular Intervention Marketed Products
  • Table 117: Medtronic SWOT Analysis, 2014
  • Table 118: Aachen Resonance Company Profile
  • Table 119: Aachen Resonance Neurovascular Intervention Marketed Product
  • Table 120: Aachen Resonance SWOT Analysis, 2014
  • Table 121: Acandis Company Profile
  • Table 122: Acandis Neurovascular Intervention Marketed Products
  • Table 123: Acandis SWOT Analysis, 2014
  • Table 124: B. Braun Company Profile
  • Table 125: B. Braun Neurovascular Intervention Marketed Product
  • Table 126: B. Braun SWOT Analysis, 2014
  • Table 127: Blockade Medical Company Profile
  • Table 128: Blockade Medical Neurovascular Intervention Marketed Product
  • Table 129: Blockade Medical SWOT Analysis, 2014
  • Table 130: Contego Medical Company Profile
  • Table 131: Contego Medical Neurovascular Intervention Marketed Product
  • Table 132: Contego Medical SWOT Analysis, 2014
  • Table 133: Gardia Medical Company Profile
  • Table 134: Gardia Medical Neurovascular Intervention Marketed Product
  • Table 135: Gardia Medical SWOT Analysis, 2014
  • Table 136: InspireMD Company Profile
  • Table 137: InspireMD Neurovascular Intervention Marketed Product
  • Table 138: InspireMD SWOT Analysis, 2014
  • Table 139: ITGI Medical Company Profile
  • Table 140: ITGI Medical Neurovascular Intervention Marketed Product
  • Table 141: ITGI Medical SWOT Analysis, 2014
  • Table 142: Medikit Company Profile
  • Table 143: Medikit Neurovascular Intervention Marketed Products
  • Table 144: Medikit SWOT Analysis, 2014
  • Table 145: Merlin MD Company Profile
  • Table 146: Merlin MD Neurovascular Intervention Marketed Product
  • Table 147: Merlin MD SWOT Analysis, 2014
  • Table 148: MicroPort Scientific Corporation Company Profile
  • Table 149: MicroPort Scientific Corporation Neurovascular Intervention Marketed Products
  • Table 150: MicroPort Scientific Corporation SWOT Analysis, 2014
  • Table 151: Minvasys Company Profile
  • Table 152: Minvasys Neurovascular Intervention Marketed Product
  • Table 153: Minvasys SWOT Analysis, 2014
  • Table 154: Neuravi Company Profile
  • Table 155: Neuravi Neurovascular Intervention Marketed Product
  • Table 156: Neuravi SWOT Analysis, 2014
  • Table 157: Optimed Company Profile
  • Table 158: Optimed Neurovascular Intervention Marketed Products
  • Table 159: Optimed SWOT Analysis, 2014
  • Table 160: Phenox GmBH Company Profile
  • Table 161: Phenox GmbH Neurovascular Intervention Marketed Products
  • Table 162: Phenox GmBH SWOT Analysis, 2014
  • Table 163: Reverse Medical Company Profile
  • Table 164: Reverse Medical Neurovascular Intervention Marketed Products
  • Table 165: Reverse Medical SWOT Analysis, 2014
  • Table 166: Sequent Medical Company Profile
  • Table 167: Sequent Medical Neurovascular Intervention Marketed Products
  • Table 168: Sequent Medical SWOT Analysis, 2014
  • Table 169: Valor Medical Company Profile
  • Table 170: Valor Medical Neurovascular Intervention Marketed Products
  • Table 171: Valor Medical SWOT Analysis, 2014
  • Table 172: Other Companies in the Neurovascular Intervention Market, 2014
  • Table 173: Neurovascular Interventions Market Sales ($m) Forecast for Japan, 2011-2020
  • Table 174: Neurovascular Interventions Market Sales ($m) Forecast for China, 2011-2020
  • Table 175: Neurovascular Interventions Market Sales ($m) Forecast for India, 2011-2020

List of Figures

  • Figure 1: Treatment Modalities - Neurovascular Interventions
  • Figure 2: Types of Stents Used for Neurovascular Interventions
  • Figure 3: Embolization Procedure Volume for Treating Intracranial Aneurysms, APAC, 2011-2020
  • Figure 4: Embolization Procedure Volume for Treating Intracranial Arteriovenous Malformations, APAC, 2011-2020
  • Figure 5: Revascularization Procedure Volume for Treating Atherosclerotic Disease, APAC, 2011-2020
  • Figure 6: Mechanical Thrombectomy Procedure Volume for Treating Acute Ischemic Stroke, APAC, 2011-2020
  • Figure 7: APAC Neurointerventional Market Distribution, 2013
  • Figure 8: Global Neurovascular Interventions Pipeline Products by Stage of Development, 2014
  • Figure 9: APAC Neurovascular Interventions Market ($m) for Treating Cerebrovascular Disease, 2011-2020
  • Figure 10: Distribution of Percentage of Patients Treated for Cerebrovascular Disease, Global, 2013
  • Figure 11: APAC Neurovascular Interventions Market Revenue ($m), 2013 and 2020
  • Figure 12: Japanese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 13: Japanese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 14: Japanese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 15: Japanese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 16: Japanese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 17: Chinese Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 18: Chinese Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 19: Chinese Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 20: Chinese Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 21: Chinese Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 22: Indian Neurovascular Interventions Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 23: Indian Embolization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 24: Indian Revascularization Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 25: Indian Mechanical Thrombectomy Device Market ($m) for Cerebrovascular Applications, 2011-2020
  • Figure 26: Indian Access Device Market ($m) for Cerebrovascular Applications, 2011-2020
Back to Top